Big day for the David lab! 🎉 Our @MolecularCell paper is out today- huge congrats to first authors @IfeAkano & Jake Hebert for leading this beautiful study uncovering SMARCA3 as a novel H3 E3 ligase that shapes heterochromatin regulation in colorectal cancer 🤩

A person’s lifetime risk for #cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists published in @NatureCancer. @PospisilikJ @Bi0lilla

Thrilled to share the results @Cancer_Cell of years of hard work to develop classifiers for all major TCGA cancer subtypes, enabling assessment of differential drug response among cancer subtypes in clinical trials.

We have postdoc positions open to study epigenetic mechanisms contributing to resistance to chemo+immuno in TNBC, and projects related to epigenetic determinants of neurodevelopmental disorders. Feel free to reach out to me here/via email. Please like and repost!

Congratulations to Van Andel Institute’s Dr. Peter Jones, VAI and @HopkinsKimmel's Dr. Stephen Baylin, and @HopkinsMedicine's Dr. Andrew Feinberg, who will receive the Harvey Prize for their groundbreaking work in cancer epigenetics! Read more: https://t.co/TV67Qlr4JM

This preprint is now published with some key additions guided by an excellent review process @NAR_Open. Also grateful to our collaborators for helping progress this one across the finish line! @suscla1 @qianthefirst @Yael_David__ @zhouwanding and others! https://t.co/OX85ljomqn

Online Now: DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk between H3K18ub and H3K9me3 to reinforce heterochromatin states https://t.co/xX336PoECe

Congratulations to the authors @RothbartLab, shows the role of UHRF1 in the redistribution of H3K9me3 following DNA hypomethylation, a lingering question in the field and may have implications for the field of aging. https://t.co/JN6hzPllkN

Two new papers from the lab to end the year! Will be posting about them both at the new place in the coming weeks. @rothbartlab.bsky.social Come join us - it’s great! #SciCommBackAgain

Time to move. See you all on Bluesky: @helink.bsky.social Let's work on getting our respective institutions and our colleagues to move as well. There is an exponential increase in members on Bluesky!! https://t.co/KZKb8MYzve

If you are interested in a faculty position in the heart of metabolism, at one of strongest and most supportive institutes focused on metabolism, epigenetics, neurodegeneration and more, VAI is recruiting at all levels!

Great place to post doc @VAInstitute

Just 2 postdocs from @DrBrianStrahl’s lab (current: me; former: @RothbartLab) with their mentor. Looking forward to joining Scott on the former postdoc/current PI list by the next #BioMethylSRC

Registration is still open for this super exciting meeting! ⭐️Unbelievable lineup of #epigenetics & #aging speakers ⭐️Opportunities for short talks ⭐️New pre-meeting dedicated to trainees w/ extra opportunities for career development & 1:1 with PIs ⭐️Special awards available!

What's new and what's next in cancer epigenetics research? Join us for the 2024 VAI Epigenetics Symposium. Our allstar speaker lineup will highlight the latest advances with a focus on mechanisms and therapeutic applications. Registration closes tomorrow! https://t.co/MZsGSckbr0

Registration closes May 10 for the VAI Epigenomics Workshop. This 3-day, hands-on, problem-based experience will immerse PhD students in the latest epigenomics research and techniques. Please share with anyone who might be interested!

Holes in the patio umbrella on the terrace ⁦@VAInstitute⁩ produced hundreds of tiny eclipse shadows for us to enjoy. ⁦@BurtonNick⁩ was right place right time to catch some on his shirt too!

A pair of medications that make malignant cells act as if they have a virus could hold promise for treating #colorectalcancer & other solid tumors, according to a new preclinical study by scientists @RothbartLab. #ColorectalCancerAwarenessMonth https://t.co/MFvI1kb1F2

"The unmet potential of DNA methyltransferase inhibition therapy in patients with solid tumors underscores the importance of our findings." Congrats to @AmericanCancer grantee @RothbartLab for this this exciting study as we come to the end of #ColorectalCancerAwarenessMonth!

New paper from the lab reveals a link between epigenetic therapy-induced viral mimicry and NFAT:AP1 signaling. Rationale for combining DNMT and EZH2 inhibitors in colon cancer. Thankful to ⁦@theNCI⁩ and ⁦@ACS_Research⁩ for supporting our work!